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Abstract
Background and Purpose: Renal oncocytoma (RO) and eosinophilic 
variant of chromophobe renal cell carcinoma (ChRCC) have overlapping 
morphologic, immunohistochemical, histochemical and ultrastructural fea-
tures. Their distinction is mandatory since RO is a benign tumor, while 
ChRCC is a low-grade malignant tumor which has metastatic potential 
and may undergo sarcomatoid transformation. The aim of this study was to 
determine expression of P53, Bcl-2 and Bax in ROs and ChRCCs and to 
explore whether these markers could be useful in differential diagnosis of 
RO and ChRCC.
Patients and Methods: We analyzed 61 cases (28 ChRCCs and 33 
ROs) by immunohistochemistry using primary antibodies to P53, Bcl-2 and 
Bax. The staining percentage and staining intensity scores were multiplied 
to give immunohistochemical staining index (ISI) .
Results and Conclusion: All specimens showed positive reaction for 
Bcl-2 and Bax. There was no significant difference in the ISI for Bcl-2 and 
P53. Statistical analysis showed significant difference in the ISI of Bax be-
tween ROs and ChRCCs. Moreover, cases of ROs had  cytoplasmic pattern 
of reaction for Bax, while the pattern of reaction for Bax in cases of ChRCCs 
was membranous.
Further studies are needed to confirm the possible use of Bax immunos-
taining in differential diagnosis of RO and ChRCC.
 
INTRoduCTIoN
Chromophobe renal cell carcinoma (ChRCC) is a low-grade malig-nant neoplasm which accounts for 5% of renal epithelial tumors. 
Two main variants are classic and eosinophilic. ChRCC has a meta-
static potential and may undergo sarcomatoid transformation, which is 
associated with more aggressive behavior (1). Renal oncocytoma (RO) 
is a benign tumor which comprises approximately 5% of all primary 
renal tumors (1). The distinction between RO and ChRCC is very im-
portant due to their different biological behavior. Overlapping morpho-
logical features of RO and eosinophilic variant of ChRCC, can often 
complicate making a correct diagnosis.Received February 20, 2014.
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P53 is known inducer of apoptosis and it is the most 
common genetic mutation found in cancers. The Bcl-2, 
in contrast, prevents apoptosis and has many interactions, 
especially with Bax, which acts to promote cell death (2). 
There have been numerous studies that explored the 
possible use of various immunohistochemical markers in 
differential diagnosis of RO and ChRCC, but there is 
currently no reliable immunohistochemical marker for 
this purpose. Our recent work revealed higher number of 
apoptotic cells in the group of ROs compared to the group 
of ChRCCs (Round table – Apoptosis, programmed cell 
death, Zagreb, 2010).
The aim of this study was to determine expression of 
P53, Bcl-2 and Bax in ROs and ChRCCs and to explore 
whether these markers could be useful in differential di-
agnosis of RO and ChRCC.
PATIENTS ANd mEThodS
The files from the University Department of Patholo-
gy, Sestre milosrdnice University Hospital Centre, Za-
greb, from the period 1999-2010, were searched for cases 
of histologically confirmed ChRCC and RO. There were 
61 cases in total (28 ChRCCs and 33 ROs). Among pa-
tients with ChRCC, 14 were females, and 14 males. Pa-
tients’ age ranged from 31-82 years (mean 59.4). Tumor 
size ranged from 0.7-17 cm (mean 6.2). Among patients 
with RO, 18 were females, and 15 males. Patients’ age 
ranged from 46-80 years (mean 63.9). Tumor size ranged 
from 0.9-8 cm (mean 3.4). All specimens were routinely 
fixed in 10% buffered formalin, embedded in paraffin, 
cut at 5-µm thickness and stained with haematoxylin and 
eosin. All cases were reviewed and the diagnosis of RO 
and ChRCC was established according to the criteria pro-
posed by 2004 WHO for classification of renal tumors 
(3). Immunohistochemistry was performed by Microwave 
Streptavidine Immunoperoxidase protocol (MSIP) in 
DAKO TechMate Horizon automated immunostainer. 
We used primary antibodies to P53 (Clone DO-7, Dako), 
Bcl-2 (Clone 124, Dako) and Bax (Clone A3533, Dako). 
Dilution of antibodies for P53 and Bcl-2 was „ready to 
use“. Antibody for Bax was diluted 1:500. Positive control 
for P53 staining was colon adenocarcinoma tissue and for 
Bax and Bcl-2 staining breast carcinoma tissue. Immuno-
histochemical analysis for P53 and Bcl-2 was performed 
on all specimens and the immunohistochemical analysis 
for Bax was performed on 20 specimens (10 ROs and 10 
ChRCCs). Immunohistochemical reaction was evaluated 
semiquantitatively on 1000 tumor cells and the percent-
age of positive cells as well as staining intensity were 
scored on a scale 0-3. The percentage of positive cells was 
designated as: 0 = no positive cells; 1 = 1-10% positive 
cells; 2 = >10-25% positive cells, 3 = more than 25% 
positive cells. Staining intensity was labelled as: 0 = no 
staining, 1 = weak staining; 2 = moderate staining; 3 = 
strong staining. The staining percentage and staining in-
tensity scores were multiplied to give immunohistochem-
ical staining index (ISI) for each case. According to lit-
erature data, four groups are formed: ISI 0 = no reaction; 
ISI 1 = weak reaction (1,2,3); ISI 2 = moderate reaction 
(4 or 6); ISI 3 = strong reaction (9) (4). Statistical analysis 
was performed using the Mann-Whitney U-test and c2-
test. The level of significance was set at p=0.05.
RESulTS
Immunohistochemical staining index for P53, Bcl-2 
and Bax is shown in Table 1. 
All specimens showed positive reaction for Bcl-2 with 
predominantely moderate reaction (ISI 2). Statistical 
analysis did not show signifficant difference in the ISI of 
Bcl-2 between ROs and ChRCCs. (p=0.315)
Immunohistochemical reaction for P53 was mostly 
weak (ISI 1) and 7 cases in both groups of tumors had ISI 
0. Statistical analysis of the P53 expression between ROs 
and ChRCCs did not show significant difference. 
(p=0.682)
All 20 specimens that were analyzed for the Bax ex-
pression showed positive reaction for this marker. The 
majority of ROs had ISI 3. Immunohistochemical reac-
tion for Bax in the group of ChRCCs was predominan-
TAble 1
Immunohistochemical staining index (ISI) for P53, Bcl-2 and Bax in renal oncocytoma (RO) and chro-














ISI 0 7 (21.2%) 7 (25%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
ISI 1 23 (69.7%) 19 (67.9%) 2 (6.1%) 4 (14.3%) 1 (10%) 4 (40%)
ISI 2 3 (9.1%) 2 (7.1%) 23 (69.7%) 19 (67.9%) 3 (30%) 5 (50%)
ISI 3 0 (0%) 0 (0%)  8 (24.2%)  5 (17.8%) 6 (60%) 1 (10%)
P53, Bcl-2 and Bax in renal oncocytoma and chromophobe renal cell carcinoma Alma Demirović et al.
Period biol, Vol 116, No 2, 2014. 175
tely weak or moderate (ISI 1 and ISI 2). Statistical analy-
sis showed signiffcantly higher ISI of Bax in ROs 
compared to ChRCCs. (p=0.022) Moreover, cases of ROs 
had cytoplasmic pattern of reaction for Bax, and the pat-
tern of reaction for Bax in cases of ChRCCs was mem-
branous (Figure 1).
dISCuSSIoN
Distinction between RO and eosinophilic variant 
ChRCC is common diagnostic problem in urologic pa-
thology. ROs and eosinophilic variant of ChRCCs have 
overlapping morphologic, immunohistochemical, histo-
chemical and ultrastructural features. Their distinction is 
mandatory since they have different biological courses. 
ChRCC has malignant potential, especially its sarcoma-
toid variant, whereas RO is a benign tumor (3). Numerous 
studies explored the possible use of many immunohisto-
chemical markers in differential diagnosis of RO and 
ChRCC such as caveolin-1, CD63, anti-mitochondrial 
antibody, cytokeratin 14, cytokeratin 7 and 20, vimentin, 
glutathione S-transferase a, CD10, CD117, claudin-7, 
claudin-8, kidney-specific cadherin, p53, progesterone, 
MAGE and Ny-ESO (5-11). Antimitochondrial antibod-
ies, parvalbumin and BCA2 are considered to be good 
markers for differentiating between these tumors (12-15). 
However, there is currently no specific immunohisto-
chemical marker for differential diagnosis of these tumors.
Few authors analyzed the immunohistochemical ex-
pression of Bcl-2 and Bax in the clear cell renal cell carci-
noma (CCRCC) with respect to established prognostic 
factors for CCRCC. Vasavada et al. found the Bcl-2 and 
Bax expression to be correlated with higher tumor grade 
but none of the other factors (tumor recurrence, metasta-
sis, survival rate) (16). In the other study the Bcl-2 expres-
sion also did not correlate with disease-free or overall 
survival. However, this group of authors found that the 
Bcl-2 expression occurred more frequently in matched 
patient metastases when compared to primary tumors 
(17).
The tumor suppressor gene p53 is essential in main-
taining the genomic integrity of cells. It is involved in 
controlling a checkpoint during the G1 phase of the cell 
cycle and induces cell cycle arrest and apoptosis in the 
presence of damaged DNA (18). Mutation of p53 has 
been reported in approximately 50% of all human can-
cers, although these mutations generally occur late in 
tumorigenesis process (19, 20). The reported range of P53 
overexpression in CCRCC varies from 0% to 40% (16, 
21-27). 
We analyzed the immunohistochemical expression of 
apoptosis-related markers P53, Bcl-2 and Bax in ROs and 
ChRCCs. All specimens showed positive reaction for Bcl-
2 and Bax. There was no significant difference in the ISI 
for Bcl-2 and P53. The results regarding Bax expression 
showed significant difference in the pattern of reaction 
and ISI between the two tumor groups, but number of 
cases is insufficient to make final conclusions. 
Further studies are needed to confirm the possible use 
of Bax immunostaining in differential diagnosis of RO 
and ChRCC.
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